Hisamitsu Pharmaceutical Co (TSE:4530) Cash-to-Debt : 106.27 (As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hisamitsu Pharmaceutical Co's cash to debt ratio for the quarter that ended in Nov. 2023 was 106.27.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hisamitsu Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

TSE:4530' s Cash-to-Debt Range Over the Past 10 Years
Min: 37.47 Med: 59.66 Max: 84.89
Current: 59.68

During the past 13 years, Hisamitsu Pharmaceutical Co's highest Cash to Debt Ratio was 84.89. The lowest was 37.47. And the median was 59.66.

TSE:4530's Cash-to-Debt is ranked better than
87.12% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs TSE:4530: 59.68

Hisamitsu Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hisamitsu Pharmaceutical Co Cash-to-Debt Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Cash-to-Debt

Get a 7-Day Free Trial

79.96

84.89

57.90

59.64

59.68

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															59.64	113.58	119.55	106.27	59.68

Competitive Comparison of Hisamitsu Pharmaceutical Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hisamitsu Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Cash-to-Debt falls into.

Hisamitsu Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hisamitsu Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	125321	/	(1421	+	679)
	=	59.68

Hisamitsu Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	123912	/	(1071	+	95)
	=	106.27

Hisamitsu Pharmaceutical Co (TSE:4530) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hisamitsu Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines